In renal cell carcinoma it has been shown that the loss of VHL and hypoxia can upregulate PAX2 expression [26].Therefore, determining factors and their signalling pathways which are involved in the progression of melanoma which can upregulate PAX2 expression, may identify new therapeutic target proteins for the treatment of melanoma patients. The gene discussed is PAX2; the disease is renal cell carcinoma.